Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

NCT03145181 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: Teclistamab (IV)
DRUG: Teclistamab(SC)

Sponsor

Janssen Research & Development, LLC